In the landmark registration study BR.21, more patients on Tarceva had improvement in cough, pain, shortness of breath and overall physical function versus patients on placebo.

• 在具有里程碑意义的BR.；21注册临床研究中，与服用安慰剂的患者相比，更多接受特罗凯治疗的患者改善了咳嗽、疼痛、呼吸困难和整个身体机能。